Literature DB >> 27208490

Amphetamine withdrawal differentially affects hippocampal and peripheral corticosterone levels in response to stress.

Brenna Bray1, Jamie L Scholl2, Wenyu Tu3, Michael J Watt4, Kenneth J Renner5, Gina L Forster6.   

Abstract

Amphetamine withdrawal is associated with heightened anxiety-like behavior, which is directly driven by blunted stress-induced glucocorticoid receptor-dependent serotonin release in the ventral hippocampus. This suggests that glucocorticoid availability in the ventral hippocampus during stress may be reduced during amphetamine withdrawal. Therefore, we tested whether amphetamine withdrawal alters either peripheral or hippocampal corticosterone stress responses. Adult male rats received amphetamine (2.5mg/kg, ip) or saline for 14 days followed by 2 weeks of withdrawal. Contrary to our prediction, microdialysis samples from freely-moving rats revealed that restraint stress-induced corticosterone levels in the ventral hippocampus are enhanced by amphetamine withdrawal relative to controls. In separate groups of rats, plasma corticosterone levels increased immediately after 20min of restraint and decreased to below stress-naïve levels after 1h, indicating negative feedback regulation of corticosterone following stress. However, plasma corticosterone responses were similar in amphetamine-withdrawn and control rats. Neither amphetamine nor stress exposure significantly altered protein expression or enzyme activity of the steroidogenic enzymes 11β-hydroxysteroid dehydrogenase (11β-HSD1) or hexose-6-phosphate dehydrogenase (H6PD) in the ventral hippocampus. Our findings demonstrate for the first time that amphetamine withdrawal potentiates stress-induced corticosterone in the ventral hippocampus, which may contribute to increased behavioral stress sensitivity previously observed during amphetamine withdrawal. However, this is not mediated by either changes in plasma corticosterone or hippocampal steroidogenic enzymes. Establishing enhanced ventral hippocampal corticosterone as a direct cause of greater stress sensitivity may identify the glucocorticoid system as a novel target for treating behavioral symptoms of amphetamine withdrawal.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  11β-hydroxysteroid dehydrogenase; Amphetamine withdrawal; Hexose-6-phosphate dehydrogenase; Psychostimulant withdrawal; Stress; Ventral hippocampus

Mesh:

Substances:

Year:  2016        PMID: 27208490      PMCID: PMC4920069          DOI: 10.1016/j.brainres.2016.05.030

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  83 in total

1.  Chronic exposure to morphine increases corticosteroid-binding globulin.

Authors:  B Nock; M Wich; T J Cicero
Journal:  J Pharmacol Exp Ther       Date:  1997-09       Impact factor: 4.030

2.  Review: limited evidence to support pharmacological therapy for amphetamine withdrawal.

Authors:  Michael Gossop
Journal:  Evid Based Ment Health       Date:  2009-11

3.  Long-term corticosteroid treatment but not chronic stress affects 11beta-hydroxysteroid dehydrogenase type I activity in rat brain and peripheral tissues.

Authors:  P H Jellinck; F S Dhabhar; R R Sakai; B S McEwen
Journal:  J Steroid Biochem Mol Biol       Date:  1997-03       Impact factor: 4.292

4.  Intracellular regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase (11beta-HSD)-1 plays a key role in regulation of the hypothalamic-pituitary-adrenal axis: analysis of 11beta-HSD-1-deficient mice.

Authors:  H J Harris; Y Kotelevtsev; J J Mullins; J R Seckl; M C Holmes
Journal:  Endocrinology       Date:  2001-01       Impact factor: 4.736

5.  Expression of corticosteroid-binding protein in the human hypothalamus, co-localization with oxytocin and vasopressin.

Authors:  E V Sivukhina; G F Jirikowski; H G Bernstein; J G Lewis; Z Herbert
Journal:  Horm Metab Res       Date:  2006-04       Impact factor: 2.936

6.  Aging increases basal but not stress-induced levels of corticosterone in the brain of the awake rat.

Authors:  Pedro Garrido; Marta de Blas; Alberto Del Arco; Gregorio Segovia; Francisco Mora
Journal:  Neurobiol Aging       Date:  2010-04-22       Impact factor: 4.673

7.  Influence of chronic amphetamine treatment and acute withdrawal on serotonin synthesis and clearance mechanisms in the rat ventral hippocampus.

Authors:  Jeffrey L Barr; Jamie L Scholl; Rajeshwari R Solanki; Michael J Watt; Christopher A Lowry; Kenneth J Renner; Gina L Forster
Journal:  Eur J Neurosci       Date:  2012-11-14       Impact factor: 3.386

8.  Central CRF2 receptor antagonism reduces anxiety states during amphetamine withdrawal.

Authors:  Emily D Reinbold; Jamie L Scholl; Kathryn M Oliver; Michael J Watt; Gina L Forster
Journal:  Neurosci Res       Date:  2014-09-06       Impact factor: 3.304

9.  HPA axis changes during the initial phase of psychosocial stressor exposure in male mice.

Authors:  Nicole Uschold-Schmidt; Daniel Peterlik; Andrea M Füchsl; Stefan O Reber
Journal:  J Endocrinol       Date:  2013-07-01       Impact factor: 4.286

10.  Corticosteroids, 11beta-hydroxysteroid dehydrogenase isozymes and the rabbit choroid plexus.

Authors:  A J Sinclair; C U Onyimba; P Khosla; N Vijapurapu; J W Tomlinson; M A Burdon; P M Stewart; P I Murray; E A Walker; S Rauz
Journal:  J Neuroendocrinol       Date:  2007-08       Impact factor: 3.627

View more
  2 in total

1.  Corticosterone in the ventral hippocampus differentially alters accumbal dopamine output in drug-naïve and amphetamine-withdrawn rats.

Authors:  Brenna Bray; Kaci A Clement; Dana Bachmeier; Matthew A Weber; Gina L Forster
Journal:  Neuropharmacology       Date:  2019-12-24       Impact factor: 5.250

2.  The Basolateral Amygdala to Ventral Hippocampus Circuit Controls Anxiety-Like Behaviors Induced by Morphine Withdrawal.

Authors:  Cuola Deji; Peng Yan; Yuanyuan Ji; Xinyue Yan; Yue Feng; Jincen Liu; Yige Liu; Shuguang Wei; Yongsheng Zhu; Jianghua Lai
Journal:  Front Cell Neurosci       Date:  2022-06-02       Impact factor: 6.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.